Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00500890 · ClinicalTrials.gov registry record · Phase 3
Treatment of Tumors of the Choroid Plexus Epithelium
A Phase 3 study, sponsored by M.D. Anderson Cancer Center.
- Terminated
- Registry status
- Phase 3
- Development phase
- 2
- Enrollment target
NCT00500890: Clinical Trial Phase 3 study, sponsored by M.D. Anderson Cancer Center.
NCT00500890 is a Phase 3 study that was terminated before completion, run by M.D. Anderson Cancer Center. The registered enrollment target is 2 participants. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT00500890, a Phase 3 study, was terminated before completion, sponsored by M.D. Anderson Cancer Center.
- TERMINATED
- Registry status
- Phase 3
- Development phase
- 2 participants
- Enrollment target
Study Summary
The goal of this clinical research study is to compare carboplatin to cyclophosphamide when given with etoposide, vincristine, and radiation therapy in the treatment of choroid plexus tumors. The safety of these 2 combination therapies will also be compared. Objectives: OVERALL AIM: To improve choroid plexus tumor treatment through better understanding of the tumor biology and through increased knowledge about the benefit of specific treatment elements. Specific Objectives: The study will have a prephase to evaluate the feasibility of the following randomized study (main phase). Pre-Phase (completed 2005) Primary Specific Objective: To determine the number of patients accountable per year for randomization in a worldwide study. Secondary Specific Objective: To measure the number of drop outs and to describe the toxicity of the chemotherapy. Main Phase (started in 2006) Primary Specific Objective: To compare the survival times after cyclophosphamide based treatment with the survival times after carboplatin based treatment in choroid plexus tumor patients. Main Phase Secondary Specific Objectives: 1. To compare the resectability of choroid plexus tumors after two blocks of cyclophosphamide based treatment with the resectability after two blocks of carboplatin based treatment. 2. To compare response rates of incompletely resected choroid plexus tumors to two blocks of cyclophosphamide based treatment with the response rates after two blocks of carboplatin based treatment. 3. To determine the prognostic relevance of histological atypia and SV40 in choroid plexus tumors.
Interventions
- DRUG Cyclophosphamide
- DRUG Carboplatin
- RADIATION Radiation Therapy
- DRUG Etoposide
- DRUG Vincristine
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 2 participants |
| Start Date | 2005-09-02 |
| Est. Completion | 2017-12-14 |
| Phase | Phase 3 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00500890
The ClinicalTrials.gov registry entry for NCT00500890 describes a study currently listed as terminated, categorized as Phase 3. The registered enrollment target is 2 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is M.D. Anderson Cancer Center, which has 2,692 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 5 interventions - of which Cyclophosphamide is the first listed.
NCT00500890 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00500890 about?
NCT00500890 is a clinical study titled "Treatment of Tumors of the Choroid Plexus Epithelium". The goal of this clinical research study is to compare carboplatin to cyclophosphamide when given with etoposide, vincristine, and radiation therapy in the treatment of choroid plexus tumors. The safety of these 2 combination therapies will also be compared. Objectives: OVERALL AIM: To improve ch...
What is the current status of trial NCT00500890?
This trial is currently terminated. It is a Phase 3 study. The enrollment target is 2 participants. The study started on 2005-09-02. Estimated completion is 2017-12-14.
What interventions are being tested in trial NCT00500890?
The interventions under investigation include: Cyclophosphamide (DRUG), Carboplatin (DRUG), Radiation Therapy (RADIATION), Etoposide (DRUG), Vincristine (DRUG).
Who is sponsoring clinical trial NCT00500890?
This trial is sponsored by M.D. Anderson Cancer Center, which has 2,692 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, the data changelog, or report a data error.